$TFFP
TFF Pharmaceuticals, Inc.

2023 Q4 Form 10-Q Financial Statement

#000121390023086896 Filed on November 14, 2023

View on sec.gov

Income Statement

Concept 2023 Q4 2023 Q3 2022 Q4
Revenue $114.3K $234.8K $312.8K
YoY Change -63.45% 168.04% 2506.5%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.509M $2.269M $3.558M
YoY Change -29.48% -32.12% 11.59%
% of Gross Profit
Research & Development $2.974M $2.387M $4.136M
YoY Change -28.09% -40.72% -40.23%
% of Gross Profit
Depreciation & Amortization $130.7K $121.8K $120.9K
YoY Change 8.07% 20.44% 56.99%
% of Gross Profit
Operating Expenses $5.483M $4.655M $7.694M
YoY Change -28.73% -36.82% -23.89%
Operating Profit -$4.421M
YoY Change -39.28%
Interest Expense $606.3K $11.36K $7.540K
YoY Change 7940.98% 85.62% -21.54%
% of Operating Profit
Other Income/Expense, Net $11.36K $0.00
YoY Change 85.59% -100.0%
Pretax Income -$4.762M -$4.409M -$7.373M
YoY Change -35.41% -39.39% -26.63%
Income Tax
% Of Pretax Income
Net Earnings -$4.762M -$4.409M -$7.373M
YoY Change -35.41% -39.39% -26.63%
Net Earnings / Revenue -4165.49% -1878.17% -2357.32%
Basic Earnings Per Share -$0.09
Diluted Earnings Per Share -$2.01 -$0.09 -$0.17
COMMON SHARES
Basic Shares Outstanding 59.13M shares 36.25M shares 25.52M shares
Diluted Shares Outstanding 47.44M shares

Balance Sheet

Concept 2023 Q4 2023 Q3 2022 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $5.478M $9.726M $16.61M
YoY Change -67.02% -26.02% -50.84%
Cash & Equivalents $5.478M $9.700M $16.61M
Short-Term Investments
Other Short-Term Assets $1.678M $805.7K $2.226M
YoY Change -24.61% -24.69% -9.05%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $7.590M $10.89M $19.03M
YoY Change -60.1% -35.84% -51.01%
LONG-TERM ASSETS
Property, Plant & Equipment $2.119M $2.064M $3.078M
YoY Change -31.15% -31.79% 65.51%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $7.690K $7.688K $7.688K
YoY Change 0.03% 0.0%
Total Long-Term Assets $4.437M $3.992M $5.095M
YoY Change -12.92% 22.9% 173.95%
TOTAL ASSETS
Total Short-Term Assets $7.590M $10.89M $19.03M
Total Long-Term Assets $4.437M $3.992M $5.095M
Total Assets $12.03M $14.89M $24.12M
YoY Change -50.14% -26.41% -40.73%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $958.4K $983.3K $919.6K
YoY Change 4.22% -39.82% -38.44%
Accrued Expenses $1.369M $82.73K $85.06K
YoY Change 1509.57% 3.62% -79.6%
Deferred Revenue $101.0K
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $2.429M $1.142M $1.131M
YoY Change 114.79% -45.0% -42.34%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $31.74K $52.23K $110.1K
YoY Change -71.17% -59.29%
Total Long-Term Liabilities $31.74K $52.23K $110.1K
YoY Change -71.17% -59.29%
TOTAL LIABILITIES
Total Short-Term Liabilities $2.429M $1.142M $1.131M
Total Long-Term Liabilities $31.74K $52.23K $110.1K
Total Liabilities $2.460M $1.194M $1.241M
YoY Change 98.29% -45.84% -36.72%
SHAREHOLDERS EQUITY
Retained Earnings -$118.3M -$113.6M -$97.09M
YoY Change 21.85% 26.62% 48.64%
Common Stock $128.0M $127.5M $36.19K
YoY Change 353689.07% 499405.76% 42.65%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $9.567M $13.69M $22.88M
YoY Change
Total Liabilities & Shareholders Equity $12.03M $14.89M $24.12M
YoY Change -50.14% -26.41% -40.73%

Cashflow Statement

Concept 2023 Q4 2023 Q3 2022 Q4
OPERATING ACTIVITIES
Net Income -$4.762M -$4.409M -$7.373M
YoY Change -35.41% -39.39% -26.63%
Depreciation, Depletion And Amortization $130.7K $121.8K $120.9K
YoY Change 8.07% 20.44% 56.99%
Cash From Operating Activities -$4.214M -$3.005M -$7.702M
YoY Change -45.29% -59.28% -29.23%
INVESTING ACTIVITIES
Capital Expenditures $46.39K $8.360K $141.2K
YoY Change -67.14% -101.08% -211.46%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$46.39K -$8.360K -$141.2K
YoY Change -67.14% -98.92% 11.46%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 560.0 5.093M 11.34M
YoY Change -100.0% 1082.35%
NET CHANGE
Cash From Operating Activities -4.214M -3.005M -7.702M
Cash From Investing Activities -46.39K -8.360K -141.2K
Cash From Financing Activities 560.0 5.093M 11.34M
Net Change In Cash -4.259M 2.080M 3.493M
YoY Change -221.94% -126.92% -131.73%
FREE CASH FLOW
Cash From Operating Activities -$4.214M -$3.005M -$7.702M
Capital Expenditures $46.39K $8.360K $141.2K
Free Cash Flow -$4.260M -$3.013M -$7.843M
YoY Change -45.68% -54.36% -27.09%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-39102
dei Entity Registrant Name
EntityRegistrantName
TFF PHARMACEUTICALS, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
82-4344737
dei Entity Address Address Line1
EntityAddressAddressLine1
1751 River Run
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 400
dei Entity Address City Or Town
EntityAddressCityOrTown
Fort Worth
dei Entity Address State Or Province
EntityAddressStateOrProvince
TX
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
76107
dei City Area Code
CityAreaCode
(817)
dei Local Phone Number
LocalPhoneNumber
438-6168
dei Security12b Title
Security12bTitle
Common stock: Par value $0.001
dei Trading Symbol
TradingSymbol
TFFP
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
59133574 shares
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
9725755 usd
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
16612315 usd
CY2023Q3 tffp Research And Development Tax Incentive Receivable
ResearchAndDevelopmentTaxIncentiveReceivable
361485 usd
CY2022Q4 tffp Research And Development Tax Incentive Receivable
ResearchAndDevelopmentTaxIncentiveReceivable
186507 usd
CY2023Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
805659 usd
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2226344 usd
CY2023Q3 us-gaap Assets Current
AssetsCurrent
10892899 usd
CY2022Q4 us-gaap Assets Current
AssetsCurrent
19025166 usd
CY2023Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
139230 usd
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
196044 usd
CY2023Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2064354 usd
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3078342 usd
CY2023Q3 us-gaap Notes Receivable Fair Value Disclosure
NotesReceivableFairValueDisclosure
1781000 usd
CY2022Q4 us-gaap Notes Receivable Fair Value Disclosure
NotesReceivableFairValueDisclosure
1812975 usd
CY2023Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
7688 usd
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
7688 usd
CY2023Q3 us-gaap Assets
Assets
14885171 usd
CY2022Q4 us-gaap Assets
Assets
24120215 usd
CY2023Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
983287 usd
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
919607 usd
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
4430 usd
CY2023Q3 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
76000 usd
CY2022Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
126000 usd
CY2023Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
82725 usd
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
80625 usd
CY2023Q3 us-gaap Liabilities Current
LiabilitiesCurrent
1142012 usd
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
1130662 usd
CY2023Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
52230 usd
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
110094 usd
CY2023Q3 us-gaap Liabilities
Liabilities
1194242 usd
CY2022Q4 us-gaap Liabilities
Liabilities
1240756 usd
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
90000000 shares
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
45000000 shares
CY2023Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
59133574 shares
CY2023Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
59133574 shares
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
36193085 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
36193085 shares
CY2023Q3 us-gaap Common Stock Value
CommonStockValue
59134 usd
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
36193 usd
CY2023Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
127404746 usd
CY2022Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
120070983 usd
CY2023Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-203712 usd
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-139295 usd
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-113569239 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-97088422 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
13690929 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
22879459 usd
CY2023Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
14885171 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
24120215 usd
CY2023Q3 us-gaap Revenues
Revenues
234763 usd
CY2022Q3 us-gaap Revenues
Revenues
87586 usd
us-gaap Revenues
Revenues
619543 usd
us-gaap Revenues
Revenues
183025 usd
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2386707 usd
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4025940 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
9087264 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
14360293 usd
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2268656 usd
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3342266 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8058235 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
10238744 usd
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
4655363 usd
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
7368206 usd
us-gaap Operating Expenses
OperatingExpenses
17145499 usd
us-gaap Operating Expenses
OperatingExpenses
24599037 usd
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-4420600 usd
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-7280620 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-16525956 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-24416012 usd
CY2023Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
88810 usd
CY2022Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
6119 usd
us-gaap Investment Income Interest
InvestmentIncomeInterest
160009 usd
us-gaap Investment Income Interest
InvestmentIncomeInterest
19184 usd
CY2023Q3 tffp Change In Fair Value Of Note Receivable
ChangeInFairValueOfNoteReceivable
-77454 usd
tffp Change In Fair Value Of Note Receivable
ChangeInFairValueOfNoteReceivable
-114870 usd
CY2023Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
11356 usd
CY2022Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
6119 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
45139 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
19184 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-4409244 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-7274501 usd
us-gaap Net Income Loss
NetIncomeLoss
-16480817 usd
us-gaap Net Income Loss
NetIncomeLoss
-24396828 usd
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.09
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.29
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.41
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.96
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
47441693 shares
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
25451691 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
39983825 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
25399352 shares
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-4409244 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-7274501 usd
us-gaap Net Income Loss
NetIncomeLoss
-16480817 usd
us-gaap Net Income Loss
NetIncomeLoss
-24396828 usd
CY2023Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-38182 usd
CY2022Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-103226 usd
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-64417 usd
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-161426 usd
CY2023Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-4447426 usd
CY2022Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-7377727 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-16545234 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-24558254 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
22879459 usd
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
751821 usd
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
17920 usd
CY2023Q1 us-gaap Temporary Equity Foreign Currency Translation Adjustments
TemporaryEquityForeignCurrencyTranslationAdjustments
-18669 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-7051367 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
16543324 usd
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
825719 usd
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
59229 usd
CY2023Q2 us-gaap Temporary Equity Foreign Currency Translation Adjustments
TemporaryEquityForeignCurrencyTranslationAdjustments
-7566 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-5020206 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
12282042 usd
CY2023Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
5064722 usd
CY2023Q3 us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
25272 usd
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
766319 usd
CY2023Q3 us-gaap Temporary Equity Foreign Currency Translation Adjustments
TemporaryEquityForeignCurrencyTranslationAdjustments
-38182 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-4409244 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
13690929 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
38737059 usd
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
1177702 usd
CY2022Q1 us-gaap Temporary Equity Foreign Currency Translation Adjustments
TemporaryEquityForeignCurrencyTranslationAdjustments
47234 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-8376002 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
31585993 usd
CY2022Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
10185 usd
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
1195081 usd
CY2022Q2 us-gaap Temporary Equity Foreign Currency Translation Adjustments
TemporaryEquityForeignCurrencyTranslationAdjustments
-105434 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-8746325 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
23939500 usd
CY2022Q3 us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
404555 usd
CY2022Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
100637 usd
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
955561 usd
CY2022Q3 us-gaap Temporary Equity Foreign Currency Translation Adjustments
TemporaryEquityForeignCurrencyTranslationAdjustments
-103226 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-7274501 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
18022526 usd
us-gaap Net Income Loss
NetIncomeLoss
-16480817 usd
us-gaap Net Income Loss
NetIncomeLoss
-24396828 usd
us-gaap Share Based Compensation
ShareBasedCompensation
2343859 usd
us-gaap Share Based Compensation
ShareBasedCompensation
3328344 usd
tffp Interest Accrued On Note Receivable
InterestAccruedOnNoteReceivable
82895 usd
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
114870 usd
us-gaap Inventory Write Down
InventoryWriteDown
747348 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
371814 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
267311 usd
us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
184272 usd
tffp Increase Decrease In Research And Development Tax Incentive Receivable
IncreaseDecreaseInResearchAndDevelopmentTaxIncentiveReceivable
211785 usd
tffp Increase Decrease In Research And Development Tax Incentive Receivable
IncreaseDecreaseInResearchAndDevelopmentTaxIncentiveReceivable
103307 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1416302 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1433966 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
66910 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
148657 usd
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-4430 usd
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-416910 usd
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-50000 usd
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
312710 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-55764 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-29869 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-11824588 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-19640198 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
48359 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1410159 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-48359 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-1410159 usd
us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
5064722 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
25272 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
404555 usd
us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
77149 usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
10185 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
5012845 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
414740 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-26458 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-11965 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-6886560 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-20647582 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
16612315 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
33794672 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
9725755 usd
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
13147090 usd
us-gaap Noncash Or Part Noncash Acquisition Accounts Receivable Acquired1
NoncashOrPartNoncashAcquisitionAccountsReceivableAcquired1
100637 usd
us-gaap Consideration Received For Beneficial Interest Obtained For Transferring Financial Asset
ConsiderationReceivedForBeneficialInterestObtainedForTransferringFinancialAsset
238021 usd
us-gaap Net Income Loss
NetIncomeLoss
-16500000 usd
us-gaap Net Income Loss
NetIncomeLoss
-24400000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-11800000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-19600000 usd
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
9700000 usd
tffp Working Capital Surplus
WorkingCapitalSurplus
9800000 usd
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-113600000 usd
tffp Proceeds From Sale Of Units
ProceedsFromSaleOfUnits
5100000 usd
CY2018Q4 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
37080 usd
tffp Research And Development Tax Percentage
ResearchAndDevelopmentTaxPercentage
0.435 pure
tffp Research And Development Tax Percentage
ResearchAndDevelopmentTaxPercentage
0.435 pure
CY2023Q3 tffp Research And Development Tax Incentive Receivable
ResearchAndDevelopmentTaxIncentiveReceivable
361485 usd
CY2022Q4 tffp Research And Development Tax Incentive Receivable
ResearchAndDevelopmentTaxIncentiveReceivable
186507 usd
CY2023Q3 tffp Reduction To Research And Development Expenses
ReductionToResearchAndDevelopmentExpenses
88947 usd
tffp Reduction To Research And Development Expenses
ReductionToResearchAndDevelopmentExpenses
211785 usd
CY2022Q3 tffp Reduction To Research And Development Expenses
ReductionToResearchAndDevelopmentExpenses
25544 usd
tffp Reduction To Research And Development Expenses
ReductionToResearchAndDevelopmentExpenses
103307 usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
2759950 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
1.06
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
341187 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
7.15
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
11533220 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3280672 shares
us-gaap Use Of Estimates
UseOfEstimates
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Use of Estimates</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The preparation of condensed consolidated financial statements in conformity with GAAP requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Significant estimates include the fair value of the convertible note receivable, stock-based compensation and warrants and the valuation allowance against deferred tax assets and related disclosures. Actual results could differ from those estimates.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i> </i></b></span></p>
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Risks and Uncertainties</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The Company’s business may be adversely affected by the continuing fallout from the COVID-19 pandemic. While the COVID-19 pandemic has abated in the last several months, many of the consequences of the COVID-19 pandemic continue to cause disruption and increased costs for businesses. In the case of clinical stage biopharmaceutical companies, the Company believes there continue to be, among other things, supply chain disruptions that are causing delays in the delivery of drug candidates and comparator products and healthcare staffing shortages that are causing delays in the establishment of test sites and the conduct of clinical trials.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Potential impacts to the Company’s business include, but are not limited to, temporary closures of facilities of its vendors, disruptions or restrictions on its employees’ ability to travel, disruptions to or delays in ongoing laboratory experiments, preclinical studies, clinical trials, third-party manufacturing supply and other operations, the supply of comparator products, the potential diversion of healthcare resources and staff away from the conduct of clinical trials to focus on pandemic concerns, interruptions or delays in the operations of the U.S. Food and Drug Administration or other regulatory authorities, and the Company’s ability to raise capital and conduct business development activities.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">During 2020, the Company experienced a temporary suspension of dosing in the Phase I clinical trial for TFF TAC due to the COVID-19 pandemic and the pandemic has otherwise caused minor slowing in the timing of certain non-clinical and clinical activities by the Company and its collaborators and service providers during 2020 to date. However, the COVID-19 pandemic has not caused the Company to forego, abandon or materially delay any proposed activities. While the Company believes it has been able to effectively manage the disruption caused by the COVID-19 pandemic to date, there can be no assurance that its operations, including the development of its drug candidates, will not be disrupted or materially adversely affected in the future by the COVID-19 pandemic or an epidemic or outbreak of an infectious disease like the outbreak of COVID-19.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">In February 2022, Russia commenced a military invasion of Ukraine causing ongoing geopolitical turmoil, including continuing military action in the region and sanctions imposed on Russia.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">These and other events have caused and may continue to cause significant disruption, instability and volatility in the global economy and financial markets, resulting in inflation, rising interest rates, tightening of credit markets and bank failures, the actual or anticipated occurrence of which may have an adverse impact on the Company’s business or ability to access capital markets in the future.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">On August 30, 2023, the Company received a notice from the Nasdaq Stock Market, LLC (“Nasdaq”) stating that the staff of the Nasdaq has determined that the Company will be eligible for an additional 180 calendar day period to regain compliance with the minimum bid price requirement in Nasdaq Listing Rule 5450(a)(1). As previously reported by the Company, on March 2, 2023, the Company received a notice (“Notice”) of delisting from the Nasdaq because the closing bid price of the Company’s common stock over the previous 30 consecutive trading-day period had fallen below $1.00 per share. Pursuant to the Notice and Rule 5810(c)(3)(A) of the Nasdaq Listing Rules, the Company had an initial 180 days from the date of the Notice, or until August 29, 2023, to regain compliance with the minimum bid price requirement in Rule 5450(a)(1) by achieving a closing bid price for the Company’s common stock of at least $1.00 per share over a minimum of 10 consecutive business days. The Company now has until February 26, 2024 to regain compliance with the minimum bid price requirement in Nasdaq listing Rule 5450(a)(1). If the Company does not regain compliance with Rule 5450(a)(1) by achieving a closing bid price for the Company’s common stock of at least $1.00 per share over a minimum of 10 consecutive business days by February 26, 2024, the Nasdaq will commence suspension and delisting procedures.<b><i> </i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"> </span></p>
us-gaap Risks And Uncertainties In Entitys Business
RisksAndUncertaintiesInEntitysBusiness
On August 30, 2023, the Company received a notice from the Nasdaq Stock Market, LLC (“Nasdaq”) stating that the staff of the Nasdaq has determined that the Company will be eligible for an additional 180 calendar day period to regain compliance with the minimum bid price requirement in Nasdaq Listing Rule 5450(a)(1). As previously reported by the Company, on March 2, 2023, the Company received a notice (“Notice”) of delisting from the Nasdaq because the closing bid price of the Company’s common stock over the previous 30 consecutive trading-day period had fallen below $1.00 per share. Pursuant to the Notice and Rule 5810(c)(3)(A) of the Nasdaq Listing Rules, the Company had an initial 180 days from the date of the Notice, or until August 29, 2023, to regain compliance with the minimum bid price requirement in Rule 5450(a)(1) by achieving a closing bid price for the Company’s common stock of at least $1.00 per share over a minimum of 10 consecutive business days. The Company now has until February 26, 2024 to regain compliance with the minimum bid price requirement in Nasdaq listing Rule 5450(a)(1). If the Company does not regain compliance with Rule 5450(a)(1) by achieving a closing bid price for the Company’s common stock of at least $1.00 per share over a minimum of 10 consecutive business days by February 26, 2024, the Nasdaq will commence suspension and delisting procedures.
CY2023Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
139230 usd
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
196044 usd
CY2023Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
82725 usd
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
80625 usd
CY2023Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
52230 usd
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
110094 usd
CY2023Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
134955 usd
CY2022Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
190719 usd
CY2023Q3 us-gaap Lease Cost
LeaseCost
43845 usd
CY2022Q3 us-gaap Lease Cost
LeaseCost
49519 usd
us-gaap Lease Cost
LeaseCost
131735 usd
us-gaap Lease Cost
LeaseCost
111092 usd
CY2023Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P1Y8M12D
CY2022Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P2Y4M24D
CY2023Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.08 pure
CY2022Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.08 pure
us-gaap Operating Lease Lease Income Lease Payments
OperatingLeaseLeaseIncomeLeasePayments
65775 usd
us-gaap Operating Lease Lease Income Lease Payments
OperatingLeaseLeaseIncomeLeasePayments
29869 usd
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5327820 shares
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.35
tffp Sharebased Compensation Arrangement By Sharebased Payment Award Option Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionOutstandingWeightedAverageRemainingContractualTerm2
P7Y7M28D
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
2252747 shares
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
18000 usd
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
91000 usd
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
38000 usd
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
147000 usd
CY2022Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
9000 usd
CY2022Q4 us-gaap Short Term Lease Commitment Amount
ShortTermLeaseCommitmentAmount
138000 usd
CY2023Q3 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
1812975 usd
CY2023Q3 us-gaap Principal Amount Outstanding Of Loans Held In Portfolio
PrincipalAmountOutstandingOfLoansHeldInPortfolio
15000000 usd
us-gaap Debt Instrument Redemption Price Percentage Of Principal Amount Redeemed
DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed
1 pure
CY2023Q3 us-gaap Notes Receivable Fair Value Disclosure
NotesReceivableFairValueDisclosure
1781000 usd
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
4.72
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y9M10D
CY2022Q2 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
35000000 usd
CY2023Q3 us-gaap Sale Of Stock Number Of Shares Issued In Transaction
SaleOfStockNumberOfSharesIssuedInTransaction
60089 shares
CY2023Q3 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
25000 usd
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
766319 usd
CY2022Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
955561 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2343859 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3328344 usd
CY2023Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
4712000 usd
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y1M6D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Period Increase Decrease Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice
1.06
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0.7
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2909057 shares
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
5.96
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y5M15D
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
24279 usd
CY2023Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
usd
tffp Change In Fair Value Of Note Receivable
ChangeInFairValueOfNoteReceivable
usd
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
25399352 shares
tffp Interest Accrued On Note Receivable
InterestAccruedOnNoteReceivable
usd
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
usd
us-gaap Inventory Write Down
InventoryWriteDown
usd
us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
usd
us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
usd
us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
usd
us-gaap Noncash Or Part Noncash Acquisition Accounts Receivable Acquired1
NoncashOrPartNoncashAcquisitionAccountsReceivableAcquired1
usd
us-gaap Consideration Received For Beneficial Interest Obtained For Transferring Financial Asset
ConsiderationReceivedForBeneficialInterestObtainedForTransferringFinancialAsset
usd
tffp Sharebased Compensation Arrangement By Sharebased Payment Award Options Granted In Period Weighted Average Remaining Contractual Term
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedInPeriodWeightedAverageRemainingContractualTerm
tffp Share Based Compensation Arrangement By Share Based Payment Award Options Granted Inperiod Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInperiodIntrinsicValue
usd
tffp Sharebased Compensation Arrangement By Sharebased Payment Award Options Cancelled In Period Weighted Average Remaining Contractual Term
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsCancelledInPeriodWeightedAverageRemainingContractualTerm
tffp Share Based Compensation Arrangement By Share Based Payment Award Options Cancelled Inperiod Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInperiodIntrinsicValue
usd
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
usd
CY2023Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
usd
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Entity Central Index Key
EntityCentralIndexKey
0001733413

Files In Submission

Name View Source Status
0001213900-23-086896-index-headers.html Edgar Link pending
0001213900-23-086896-index.html Edgar Link pending
0001213900-23-086896.txt Edgar Link pending
0001213900-23-086896-xbrl.zip Edgar Link pending
f10q0923ex31-1_tffpharma.htm Edgar Link pending
f10q0923ex31-2_tffpharma.htm Edgar Link pending
f10q0923ex32-1_tffpharma.htm Edgar Link pending
f10q0923ex4-1_tffpharma.htm Edgar Link pending
f10q0923_tffpharma.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
image_001.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
f10q0923_tffpharma_htm.xml Edgar Link completed
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
tffp-20230930.xsd Edgar Link pending
tffp-20230930_cal.xml Edgar Link unprocessable
tffp-20230930_lab.xml Edgar Link unprocessable
tffp-20230930_def.xml Edgar Link unprocessable
tffp-20230930_pre.xml Edgar Link unprocessable